Transcriptomics

Dataset Information

47

Expression data from colonic biopsy samples of infliximab treated UC patients


ABSTRACT: A gene expression profiling sub-study was conducted in which colonic biopsy samples were collected for RNA extraction and hybridization to microarrays from 48 patients with UC who were participating in ACT 1, a placebo-controlled study of infliximab. Gene expression profiles from infliximab responders were compared with those of baseline and infliximab non-responder samples. Infliximab had a significant effect on mRNA expression in treatment responders, with both infliximab dose and duration of treatment having an effect. Genes affected are primarily involved with inflammatory response, cell-mediated immune responses, and cell-to-cell signaling. Infliximab non-responders had a molecular phenotype that closely resembled that of untreated patients with UC. Unlike responders, non-responders do not effectively modulate TH1, TH2, and TH17 pathways. Gene expression can differentiate placebo and infliximab responders. Overall design: Patients with moderate-to-severe, active UC were treated with infliximab or placebo at weeks 0, 2, 6 and every 8 weeks thereafter. Biopsy samples (n=113) were collected from 48 patients at baseline, weeks 8 and 30 for RNA extraction and microarray analysis.

INSTRUMENT(S): [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

ORGANISM(S): Homo sapiens  

SUBMITTER: K Li  

PROVIDER: GSE23597 | GEO | 2011-07-22

SECONDARY ACCESSION(S): PRJNA131739

REPOSITORIES: GEO

Similar Datasets

2011-07-21 | E-GEOD-23597 | ArrayExpress
2013-04-01 | E-GEOD-45468 | ArrayExpress
2009-08-25 | GSE12251 | GEO
2009-09-05 | E-GEOD-12251 | ArrayExpress
2007-10-09 | E-GEOD-8350 | ArrayExpress
2007-10-10 | GSE8350 | GEO
2014-08-04 | E-GEOD-12251 | ExpressionAtlas
2014-12-22 | E-GEOD-51785 | ArrayExpress
2010-01-06 | E-GEOD-14580 | ArrayExpress
2010-01-07 | GSE14580 | GEO